Li Malmberg
Geen lopende functies
Loopbaan van Li Malmberg
Eerdere bekende functies van Li Malmberg
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CELGENE | Corporate Officer/Principal | - | - |
| XILIO THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2021 | - |
| ABBVIE INC. | Corporate Officer/Principal | - | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | 05-02-2020 | - |
Opleiding van Li Malmberg
| University of Minnesota Twin Cities | Doctorate Degree |
| University of Illinois | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Corporate Officer/Principal | 3 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| ABBVIE INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Beurs
- Insiders
- Li Malmberg
- Ervaring
